Aim: The aim of the project is to find the prevalence, clinical profile and 12-month survival of patients on dialysis in Zimbabwe. This project will define the burden of dialysis across Zimbabwe, establishing: 1. the number of prevalent patients on dialysis (both haemodialysis and peritoneal dialysis) in Zimbabwe; 2. the demographics of this dialysis population, including the diagnosed causes of ESKD; 3. the 12-month survival of these prevalent dialysis patients; 4. the annual incidence of new dialysis patients in Zimbabwe, including both those requiring temporary dialysis for acute kidney injury and those entering maintenance dialysis programs. Method: This project is an observational cohort study and involves all dialysis units in Zimbabwe, both public and private. The study population will comprise of adult patients dialysing at the dialysis units or undergoing dialysis at home. The study will be conducted over 24 months and all participants, both prevalent and incident patients will be foll

This project will analyse and describe the impact of the United Nations (UN) Convention on the Elimination of all forms of Discrimination Against Women (CEDAW) periodic review process on the health and health-related human rights of women and girls in countries of the Asia-Pacific region.

Research shows that Scheduled Tribes (ST) face high levels of chronic undernutrition, anaemia and iodine deficiency, as well as malaria. Geographical and socio-economic constraints mean that the toll of infectious diseases like tuberculosis, hepatitis, and HIV/AIDS can be uniquely high among these populations in some parts of the country, accompanied by a concomitant doubling in the prevalence of overweight/obesity across genders in ST populations. In addition to this, one in four tribal people has hypertension (figures are significantly higher in Gujarat and Kerala), and both the consumption of tobacco (10-18 points higher) and alcohol (14-21 points higher) greater as compared to non-tribal people. While great gains have been made in both understanding and eradicating disease burdens for these populations, health systems studies, and studies assessing service utilization and delivery are limited. Further, Community Health Workers or ASHAs, have helped in improving maternal and child health outcomes as wel

Background:Patients with advanced chronic kidney disease (CKD), including end-stage kidney disease (ESKD) patients receiving dialysis, are at increased risk of cardiovascular mortality, thrombotic cardiovascular events, and major bleeding complications. No trial has investigated effectiveness of antithrombotic agents in the prevention of cardiovascular events or death specifically in people with advanced stages of CKD or ESKD.Aim:To determine whether low dose rivaroxaban (2.5 mg twice daily), compared to placebo, significantly reduces the risk of a composite outcome of;Cardiovascular death,Non-fatal myocardial infarction,Stroke, orPeripheral arterial disease events,in patients with CKD stages 4 or 5 or dialysis-dependent ESKD, and an elevated cardiovascular risk (marked by the presence of coronary artery disease or peripheral arterial disease, or non-haemorrhagic non-lacunar stroke OR diabetes mellitus OR age ≥65 years).Research Methodology:The TRACK trial is an investigator-initiated, multicentre, internat